Business Description
Aquestive Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US03843E1047
Total Employee Number:
147Compare
Compare
Traded in other countries / regions
AQST.USA Index Membership
Russell 2000Russell 3000Russell 2000 IPO Date
2018-07-25Description
Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 2.54 | |||||
Equity-to-Asset | -0.24 | |||||
Debt-to-Equity | -1.28 | |||||
Debt-to-EBITDA | -0.84 | |||||
Piotroski F-Score | 3/9 | |||||
Altman Z-Score | -2.92 | |||||
Beneish M-Score | -3.79 | |||||
WACC vs ROIC | ||||||
Growth Rank
6/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -24.7 | |||||
3-Year EBITDA Growth Rate | 8.6 | |||||
3-Year EPS without NRI Growth Rate | 11.4 | |||||
3-Year FCF Growth Rate | -25.2 | |||||
3-Year Book Growth Rate | 49.6 | |||||
Future 3-5Y EPS without NRI Growth Rate Estimate Industry Rank | 22.25 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 31.9 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 26.11 | |||||
9-Day RSI | 32.03 | |||||
14-Day RSI | 36.82 | |||||
3-1 Month Momentum % | 23.59 | |||||
6-1 Month Momentum % | 55.25 | |||||
12-1 Month Momentum % | 18.08 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 4.1 | |||||
Quick Ratio | 3.85 | |||||
Cash Ratio | 3.49 | |||||
Days Inventory | 148.77 | |||||
Days Sales Outstanding | 59.12 | |||||
Days Payable | 305.35 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -30.6 | |||||
Shareholder Yield % | -18.77 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 63.45 | |||||
Operating Margin % | -111.18 | |||||
Net Margin % | -137.08 | |||||
EBITDA Margin % | -102.71 | |||||
FCF Margin % | -88.16 | |||||
OCF Margin % | -87.2 | |||||
ROA % | -52.12 | |||||
ROIC % | -225.28 | |||||
3-Year ROIIC % | 164.63 | |||||
ROC (Joel Greenblatt) % | -569.03 | |||||
ROCE % | -50.67 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 6 |
GF Value Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 8.33 | |||||
EV-to-EBIT | -7.57 | |||||
EV-to-EBITDA | -7.64 | |||||
EV-to-Revenue | 7.85 | |||||
EV-to-Forward-Revenue | 7.52 | |||||
EV-to-FCF | -8.9 | |||||
Price-to-GF-Value | 1.74 | |||||
Earnings Yield (Greenblatt) % | -13.21 | |||||
FCF Yield % | -9.6 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:AQST
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Aquestive Therapeutics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 50.271 | ||
| EPS (TTM) ($) | -0.61 | ||
| Beta | 1.5319 | ||
| 3-Year Sharpe Ratio | 0.73 | ||
| 3-Year Sortino Ratio | 1.31 | ||
| Volatility % | 87.87 | ||
| 14-Day RSI | 36.82 | ||
| 14-Day ATR ($) | 0.201815 | ||
| 20-Day SMA ($) | 4.1315 | ||
| 12-1 Month Momentum % | 18.08 | ||
| 52-Week Range ($) | 2.93 - 7.55 | ||
| Shares Outstanding (Mil) | 125.47 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Aquestive Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Aquestive Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-06 08:00 | In 106 days | ||
| Third quarter earnings results for 2026 | 2026-11-05 | In 104 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-12 08:00 | In 20 days | ||
| Second quarter earnings results for 2026 | 2026-08-11 | In 18 days | ||
| General meeting for 2026 | 2026-06-10 09:30 | 3.99 (+1.27%) | ||
| First quarter earnings conference call for 2026 | 2026-05-14 08:00 | 4.13 (-2.59%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 4.16 (-3.48%) | ||
| Citizens Life Sciences Conference | 2026-03-10 08:25 | 4.29 (+4.13%) | ||
| Guidance call for 2026 | 2026-03-09 10:40 | 4.22 (+1.20%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-05 08:00 | 4.37 (+6.07%) |
Show
Entries
Aquestive Therapeutics Inc Frequently Asked Questions
What is Aquestive Therapeutics Inc(AQST)'s stock price today?
The current price of AQST is $3.68. The 52 week high of AQST is $7.55 and 52 week low is $2.93.
When is next earnings date of Aquestive Therapeutics Inc(AQST)?
The next earnings date of Aquestive Therapeutics Inc(AQST) is 2026-08-11 Est..
Does Aquestive Therapeutics Inc(AQST) pay dividends? If so, how much?
Aquestive Therapeutics Inc(AQST) does not pay dividend.
Guru Commentaries on NAS:AQST
No articles.
Press Release
Articles on Aquestive Therapeutics Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers